Boards

Kelly Chibale’s influential presence on various boards is a testament to his commitment to guiding organisations through dynamic challenges. As we explore his past and present board memberships, we gain insights into his strategic contributions that have shaped healthcare, pharmaceuticals and global health initiatives.

Kelly’s role in these boards reflects his enduring dedication to fostering innovation and impactful decision-making across different domains.

These include:
  • Member of the Board of Directors of the Global Health Innovation Institute (GHII), Shanghai, China, 2025-date
  • Swiss Tropical and Public Health Institute (Swiss TPH) External Review Board: 2013 and 2017-2020
  • South African Health Products Regulatory Authority (SAHPRA) Board: 2017-2019
  • Chemical Process Technologies (CPT)-Pharma Board: 2022-date

Committees/Scientific Advisory Boards

Embark on a journey through Kelly Chibale’s impactful contributions to various committees and scientific advisory boards, showcasing his expertise and leadership in shaping scientific endeavors.

These carefully selected roles represent Kelly’s commitment to advancing research, innovation, and strategic decision-making within the scientific community.

Delve into the narrative of his significant roles, highlighting his dedication to steering progress in diverse scientific domains.

2025-date:  Interim Co-Chair of the International Pandemic Preparedness 100 Days Mission Therapeutics Development Coalition.

2025-date: Chair, Advisory Council of the African Diaspora Network African Scientific Community Engagement.

2024-date: Member of the Scientific Advisory Board of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Germany.

2024-date: Editorial Advisory Board member, Journal of the American Chemical Society.

2024-date: Member of the Scientific Advisory Board of INTREPID Alliance – a non-profit consortium of innovative biopharmaceutical companies dedicated to accelerating the pipeline of antiviral treatments to help protect the world ahead of future pandemics

2024-date: Member of the 100 Days Mission Science and Technology Expert Group (STEG) created to support the International Pandemic Preparedness Secretariat – a wholly independent entity that serves to join up relevant states, the private sector, and global health institutions in support of the 100 Days Mission

2024-date: Member of the Scientific Advisory Board of Global Health Drug Discovery Institute (GHDDI), Beijing, China

2022-date: Member of the Scientific Advisory Panel for the Sir Howard Dalton Centre for Translational Mechanistic Enzymology (AMR discovery translation), University of Warwick, UK.

April 2021 – current: AfroTherapeutics board

2019 – current: H3D Foundation board

April 2010 – current: H3D Research Management Team

Historical Memberships

1999

  • Temporary Advisor to the World Health Organisation (WHO) as member of scientific working group on kinetoplastid drug discovery and development, Heidelberg (Germany), 14-16 October 1999.

2006

  • Scientific Advisor to the Council for Scientific and Industrial Research (CSIR) Biosciences as a member of the Research Advisory Panel, 2006-2009.
  • Co-opted member of the Research Strengthening Group of the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, 2006.
  • Temporary Advisor to the World Health Organisation as a Member of the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases Informal Consultation Meeting on Experts to Advise the WHO on the Proposed Helminth (Parasitic Worm) Initiative to enhance Research & Development (R & D) for new products, 23-25 March 2006, University of Tokyo, Japan.

2007

  • Temporary Advisor to the World Health Organisation (WHO) as a Member of the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases Scientific Working Group Follow up Meeting on the Proposed Helminth (Parasitic Worm) Initiative to enhance R & D for new products, 22-24 January 2007, University of Tokyo, Japan.
  • Temporary Advisor to the World Health Organisation as a Member of the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) Scientific Working Group at the Informal Consultation on the new TDR Strategy, 16-17 April 2007, Geneva, Switzerland.
  • Member of the Task Force on Helminth Drug Initiative of the World Health Organisation, 1 November 2007-2010.

2009

  • Member of the Medicines for Malaria Venture (MMV) Expert Scientific Advisory Committee (ESAC), 2009-2014.
  • Member of the World Health Organisation (WHO) Antimicrobial Resistance Working Group, 2009-2012.

2012

  • Symposium Chair and Co-Organiser (with John Butera), American Chemical Society (ACS) symposium entitled “Challenges in Phenotypic Whole Cell High Throughput Screening and Medicinal Chemistry Optimisation of Hits; Strategies to Discover Novel Antiparasitic and Antimycobacterial Agents”, 243rd ACS National Meeting 25-29 March 2012, San Diego, California, USA.
  • Editor-In-Chief of book: Drug Discovery in Africa, eds. Chibale K., Masimirembwa C. and Davies-Coleman, M., Springer: Germany (2012).

2014

  • Speaker on University-Industry Collaborations, National Workshop on the Development of the National Research, Science and Technology Programme for Namibia, 24-25 March 2014, Windhoek, Namibia.
  • Symposium Chair and Co-Organiser, “Neglected Diseases” at the XXIIIrd International Symposium on Medicinal Chemistry (EFMC-ISMC 2014), 7-11 September 2014 in Lisbon, Portugal.
  • Panellist, on panel discussion: “Improving the impact of the best science for the most neglected Diseases” Organised on the occasion of the Swiss Commission for Research Partnerships with Developing Countries (KFPE)’s 20th anniversary event, 25 September 2014, Basel, Switzerland.

2015

  • Guest Editor, New Developments in Antiinfectives Research for Tropical Infectious Diseases, Symposia-In-Print, Bioorganic & Medicinal Chemistry, 2015.

2016

  • Symposium Co-Chair and Co-Organiser (with Leann Tilley and Philip Rosenthal), Keystone Symposium, Drug Discovery for Parasitic Diseases, 24-29 January 2016, Granlibakken Resort, Tahoe City, California, USA.
  • Editorial Advisory Board Member, Journal of Medicinal Chemistry, 2017-2020.
  • Expert Advisory Board Member, United Kingdom (UK) Department of Health Global Antimicrobial resistance (AMR) Innovation Fund, 2016-2020.

2019

  • Editor, Annual Reports in Medicinal Chemistry, Medicinal Chemistry Approaches to Tuberculosis and Trypanosomiasis Volumes 52 2019.
  • Editor, Annual Reports in Medicinal Chemistry, Medicinal Chemistry Approaches to Malaria and Other Tropical Diseases Volumes 53, 2019.

2020

  • Advisory Board Member, Chemical Society Reviews, 2020-2022.
  • Editorial Advisory Board Member, ACS Medicinal Chemistry Letters, 2020-2022.

2021

  • Associate Editor, Journal of Medicinal Chemistry, 2021-2022.
  • Member of the Advisory Committee, Rethinking Malaria in the Context of COVID–19, convened by Harvard University’s Defeating Malaria: From the Genes to the Globe Initiative, and co-sponsored with the World Health Organisation (WHO), 2021-2022.

2022

  • Symposium Co-Chair and Co-Organiser (with David A. Fidock and Elizabeth A. Ashley), Keystone Symposium, Malaria: Confronting Challenges From Drug Discovery to Treatment, 10-13 April 2022, Beaver Run Resort, Breckenridge, Colorado, USA.

2023

  • Member of the International Scientific Committee of the XXVIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2024) to be held in Rome, Italy, (September 1 to 5 2024), 2023.

2024

  • Elected to the United States (US) National Academy of Medicine (NAM).

2025

  • Awarded Honorary Doctorate of the Faculty of Science, Faculty of Social Sciences and Leiden University Medical Centre, Leiden University (Netherlands).
  • Elected to the United States National Academy of Sciences as one of thirty (30) International Members, and selected as an American Society of Tropical Medicine & Hygiene (ASTMH) Distinguished International Fellow.
  • Invited to be admitted as an Honorary Fellow of the Royal Society of Chemistry (UK) in recognition of profound leadership and influence on chemical science and society.